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Abstract
Background: Food allergies are a major component of the burden of allergic disease. Accurate risk assessment for
prediction of future clinical reactivity or clinical tolerance is limited by currently available techniques. Recent studies suggest
that constitutively elevated global serum levels of IL-10, a cytokine that down-regulates both Th1 and Th2 cytokine
production, may be useful in identifying human clinical tolerance to foods.
Objective: Determine the usefulness of constitutive IL-10 levels as a marker of clinical tolerance to peanut in children and
adults.
Methodology/Principal Findings: 107 subjects who were clinically tolerant to peanut and 94 subjects who were clinically
allergic to peanut participated. Plasma was analyzed via ELISA to quantify the frequency of individuals with constitutive IL-
10 levels and the intensity of those responses. The data were then stratified by age, gender and clinical status to assess the
utility of this putative biomarker in specific at-risk groups. All 201 subjects had readily quantified plasma IL-10. Levels were
no higher in subjects who were clinically tolerant to peanut than those in individuals clinically allergic to peanut.
Stratification by age, gender or both did not improve the capacity of IL-10 levels to identify clinical tolerance to peanut.
Conclusions/Significance: Plasma IL-10 levels are neither a useful biomarker of clinical tolerance to peanut nor a potential
tool for identification of clinical tolerance to peanut in humans.
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Introduction
Peanut allergy is a leading cause of fatal anaphylaxis [1] and
affects approximately 1.2 to 1.5% of people in North America and
the United Kingdom [2,3]. The methods most commonly used for
risk assessment include a detailed medical history of symptoms
after peanut exposure, a skin prick test to peanut and
quantification of peanut specific IgE in serum [4]. These tests
are used in combination, as there is the potential for diagnostic
error with reliance on any single method in isolation. Skin prick
tests or peanut specific IgE levels are unable to differentiate
reliably between sensitization to peanut, which is common, and
risk of systemic allergic reaction to peanut, which is considerably
less common [5–7]. While time consuming, costly and potentially
risky, double blind placebo controlled food challenges (DBPCFC)
are the gold standard for identification of clinical reactivity to
peanut or other foods. However, DBPCFC are performed under
standardized conditions in a healthcare setting and are not 100%
predictive of clinical reactions in the community. In addition, the
severity of clinical reactions experienced upon accidental exposure
in the community does not necessarily correlate well with the
severity as assessed during low dose allergen challenge in the clinic
[6,8].
Erroneously classifying patients as low risk for clinical reactivity
to peanut presents obvious problems, while erroneously classifying
them as high risk based on low or moderate sensitization to peanut
leads to a negative psychosocial impact and reduced quality of life
[9,10]. Given that the prevalence of patients with clearly positive
skin prick tests to peanut is some 10-fold higher than those with
verifiable clinical peanut allergy [11], there is great interest in
development of new quantitative tools to complement current
methods of peanut allergy assessment. No single biomarker with
sufficient sensitivity and specificity is currently available for
identifying clinical reactivity to peanut.
Identification of novel biomarkers that would reliably allow
determination of clinical status and/or disease severity is a major
focus in many areas of biomedical research. Most of this work has
concentrated on identification of biomarkers that associate with
disease pathogenesis or exacerbation rather than clinical
tolerance. Markers with sufficient sensitivity and specificity to
offer clinical utility have been sought for cancers [12],
tuberculosis [13], transplantation [14], eclampsia [15] and
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in innate and adaptive immune responses that is capable of
inhibiting both Th1 and Th2-like cytokine responses, a variety of
immune effector mechanisms and expression of inflammatory or
autoimmune disorders [17]. Enhanced or differential IL-10
production has been linked to clinical tolerance in animal models
and humans in multiple systems [18,19]. These observations have
led several groups to seek evidence of differential systemic serum
or plasma IL-10 levels as biomarkers in conditions ranging from
pre-eclampsia and systemic lupus erythematosus [15,16] to food
allergy [20].
In a recent clinical study involving 12 DBPCFC-negative
subjects and 29 adults who were clinically allergic to hazelnut,
Alonso et al. [20] proposes the use of constitutive serum IL-10
levels as a marker of clinical tolerance in hazelnut allergy. They
report that serum IL-10 levels greater than 2.28 pg/ml were
diagnostic of clinical tolerance, with this approach exhibiting
sensitivity of 82% and specificity of 70%.
While IL-10 is clearly an important component of immune
regulation, given the wide variety of innate and adaptive
immune cells that produce IL-10, the extensive range of
environmental stimuli and the many individual antigens to
which humans are exposed daily, it seemed unlikely to us that
constitutively elevated IL-10 levels would provide a useful tool
to discriminate between clinical tolerance and food allergy to
any single antigen. Here, in more than 200 adults and children
who were either clinically tolerant or clinically allergic to
peanut, we quantified endogenous IL-10 levels to assess the
potential utility of elevated IL-10 as a reliable biomarker of
clinical tolerance to peanut.
Methods
Ethics statement and Study populations
This study was approved by the University of Manitoba
Research Ethics Board. Before enrolment, written informed
consent was obtained from 56 adults and from parents of 145
children. Subjects were divided into study groups based on their
age and clinical reactivity to peanut. Peanut allergic subjects
(History positive/SPT positive: Hx+SPT+) had anaphylaxis upon
peanut exposure within the past 5 years, had peanut skin prick
tests (SPT, following epicutaneous testing with 1:10 wt/vol
peanut/glycerin extract (Hollister-Steir, Spokane WA) of
.3 mm wheal in comparison to the negative saline control and
frequently had peanut specific ImmunoCAP values .0.35 kUa/L.
Many of these peanut allergic subjects also had positive skin tests
or clinical symptoms to additional unrelated allergens. 94 subjects
were recruited fitting this definition. One hundred and seven
clinically tolerant, unsensitized subjects (History/SPT negative:
Hx2SPT2) were recruited on the basis of a detailed history
consistent with a lack of clinical reactivity to peanut, negative skin
prick tests to peanut, and peanut specific IgE ImmunoCAP results
,0.35 kUa/L. These participants took no precautions to avoid
peanut, and ingested it without developing any symptoms or signs.
Plasma IL-10 quantification
Fifty and 20 ml of peripheral blood were obtained by
venipuncture from adults and children, respectively. Plasma was
isolated by centrifugation. Human plasma IL-10 cytokine levels
were quantified in an assay optimized to provide sensitivity
,5.0 pg/mL with interassay variability of 5–10% (BioLegend San
Diego, CA) essentially as described in Stefura et al. [21] but using
JES3-9D7 as capture reagent. Statistical analysis was performed
using Prism 5 (GraphPAD Software, San Diego, CA).
Results
The median ages and range of the study populations were as
follows: control children (13, 12–15 y), control adults (29, 18–
46 y), peanut allergic children (10, 1–17 y) and adults (31, 18–
56 y). To determine if plasma IL-10 differed significantly between
populations who were clinically tolerant to peanut versus those
exhibiting clear clinical histories of symptoms and signs after
peanut ingestion, positive SPTs to peanut allergen, and elevated
peanut specific IgE, the plasma from each group was analyzed to
quantify constitutive IL-10 levels using a high sensitivity ELISA.
No difference was evident in the frequency of constitutive IL-10
producers between clinically tolerant and peanut allergic popula-
tions. IL-10 was detectable in all 201 subjects, with levels ranging
12 to 9860 pg/ml. Moreover, no quantitative difference in IL-10
levels was evident between the two clinical groups (median
response: Hx2SPT2, 197 pg/ml; Hx+SPT+, 128 pg/ml, p=0.2)
(Figure 1).
Food allergy prevalence is strongly influenced by age and
gender. Therefore, we carried out a subanalysis stratifying the
populations to test the hypothesis that in vivo IL-10 levels could
provide a useful cytokine biomarker to diagnose clinical tolerance
to peanut within specific at-risk groups. The putative effect of
gender on IL-10 levels in the two phenotypes was analyzed, as
shown in Figure 2. Plasma IL-10 levels did not differ significantly
between peanut-tolerant and peanut allergic adults in men or in
women, data not shown). Similarly, plasma IL-10 levels did not
differ significantly between peanut tolerant and peanut allergic
children, either in males (p=0.6) or in females (p=0.7). Thus
within both pediatric and adult, male or female, populations no
differences can be detected between plasma IL-10 levels of peanut
allergic vs peanut-tolerant individuals.
Given that peanut allergy, unlike most food allergies, is typically
life long, we also sought evidence of age-related differences in
plasma IL-10 levels (Figure 3). As seen above, plasma IL-10 levels
were not significantly different between adults who were clinically
tolerant to peanut and those who were clinically allergic (p=0.25).
Plasma IL-10 levels were also indistinguishable between children
who were clinically tolerant to peanut and those who were
Figure 1. Clinically peanut-tolerant individuals do not exhibit
higher plasma IL-10 levels. Clinically peanut-tolerant (history 2,
SPT 2, circles, n=107) and peanut-allergic (history+, SPT+, squares,
n=94) individuals are shown with bars indicating median values.
doi:10.1371/journal.pone.0011192.g001
Clinical Tolerance Biomarker
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putative biomarker was not inherently more useful in one specific
age group versus another. Plasma IL-10 levels were not linked to
age in this cross sectional analysis when comparing clinically
tolerant adults and children (p=0.23). However, interestingly,
plasma IL-10 levels were significantly lower in peanut-allergic
adults relative to peanut-allergic children (p=0.021).
Discussion
We report that elevated plasma IL-10 levels, suggested as a
useful biomarker of clinical tolerance to tree nuts in a study of 41
subjects [20], do not successfully discriminate between those with
convincing histories of clinical reactions to peanut vs those who
ingest and tolerate peanut as part of their usual diet. In this
population of 201 subjects, we also conducted sub-analyses
targeting the potential utility of this biomarker in specific at-risk
groups based on age or gender. None of these analyses supported
the hypothesis that elevated plasma IL-10 levels provide a useful
diagnostic tool to help identify clinical tolerance to peanut.
In many countries, peanut allergy poses the greatest risk of
anaphylaxis of all food allergies [1,22]. At the same time, the
frequency of sensitized but clinically tolerant individuals in the
population greatly exceeds that with clinical peanut allergy,
emphasizing the need for better tests to complement skin prick
tests and measurement of specific IgE levels in positively
identifying food allergy. Oral peanut challenges are costly, time-
consuming and are not without risk [6]. They are also performed
under optimal clinical conditions; for example, a challenge would
not be performed if a patient had an acute infection, even an
upper respiratory tract infection, or if a patient had asthma
symptoms on the day of the challenge. As such, they are not
completely predictive of clinical reactivity in the real world. These
and other factors limit their use, particularly in an allergy practice
setting [22,23]. Both skin testing and ImmunoCAP peanut specific
IgE data yield large proportions of individuals in the ‘‘gray’’ areas
characterized by poor positive and negative predictive values.
Reports suggesting that serum IL-10 might act as a biomarker
for clinical tolerance are reasonable based on extensive studies in
murine and human systems. IL-10 is capable of suppressing
production of Th1 and Th2 associated cytokines, and there is
extensive evidence suggesting a role for elevated IL-10 in immune
tolerance [18,19,22,24,25]. It is important to note however, that
most of the studies that suggest a role for elevated IL-10 levels in
tolerance are derived from antigen-specific systems rather than
from analysis of systemic IL-10 levels which we believe are more
likely to reflect the net immune response of the organism to the
millions of immunogenic stimuli encountered. In our well-powered
population, constitutive plasma IL-10 levels did not provide a
useful marker of clinical tolerance to peanut. Similarly, sub-
analyses stratifying by age also failed to demonstrate utility for
elevated plasma IL-10 levels in assessing clinical tolerance.
Interestingly, among peanut allergic, but not peanut-tolerant
subjects, lower plasma IL-10 levels were found to be associated
with age, median levels falling by half from 140 pg/ml to 60 pg/
ml (p=0.021). Summers et al in a retrospective, cross-sectional
analysis of over 1000 patients to determine which clinical and
laboratory parameters best predict the likelihood of severe allergic
reactions found enhanced significant relationships between age
(adults vs. children) and increased upper, lower respiratory tract or
systemic symptoms of anaphylaxis [26]. An important caveat to
interpretation of such results is that these studies are cross-sectional
rather than longitudinal. Nevertheless, collectively the findings
raise the speculative possibility that with long term persistence of
food allergy, the capacity of peanut allergic patients to reverse or
‘‘grow out of’’ their clinical reactivity to peanut may be associated
with inherently inferior anti-inflammatory IL-10 production.
Prospective longitudinal studies will be required to definitively
address this question.
Subanalyses focussed on gender also failed to demonstrate utility
for this approach in diagnosis of clinical tolerance to peanut. While
recent evidence shows that the severity of symptoms elicited by
Figure 2. Gender differences do not reveal significantly
different plasma IL-10 levels between children who were
clinically tolerant to peanut and those who were peanut-
allergic. Male (history 2 SPT2, n=37; history+, SPT+, n=37) and
female (history 2 SPT2, n=40; history+ SPT+, n=23). Bars indicate
medians.
doi:10.1371/journal.pone.0011192.g002
Figure 3. Persistent peanut allergy is associated with lower
plasma IL-10 levels. Clinically peanut-tolerant (history 2 SPT2)
(children, n=84; adults, n=23) and peanut-allergic (history+, SPT+)
(children, n=61; adults, n=33) are compared.
doi:10.1371/journal.pone.0011192.g003
Clinical Tolerance Biomarker
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there is longstanding epidemiological evidence that while males
clearly dominate in early life, the prevalence of food allergies and
anaphylaxis overall is higher in females, with a 60:40 ratio for
female to male patients [[Review, 27]]. Alternatively others argue
that the diagnosis of anaphylaxis can be frequently missed in
young infants or children who cannot describe their symptoms.
Fatality series focused on food-triggered anaphylaxis do not show a
strong female predominance [1]. Here, stratification by gender
fails to reveal differences or trends in plasma IL-10 levels between,
or within, clinical phenotypes.
In the past, attempts at using biomarkers that are not specific to
the disease or specific allergen(s) in question have often shown a
lack of usefulness in predicting future events. Total IgE was once
measured for the diagnosis of allergy, until it was shown that these
levels are poorly predictive of clinical status because they vary
substantially depending on gender, race, and other variables,
making decision point cut-offs impossible to establish [28].
Elevated serum biomarkers may have a tenuous correlation with
allergen-driven responses, making their use difficult [29]. Inter-
estingly, recent studies which aimed to use serum IL-10 as a
biomarker in drug allergy found no difference between IL-10
plasma levels in clinically tolerant vs. penicillin-allergic subjects
[30]. Sharply elevated, rather than reduced, IL-10 levels were
evident amongst 36 patients who presented to emergency
departments with severe acute anaphylaxis episodes [31]. These
results emphasize how challenging identification of validated
antigen non-specific diagnostic biomarkers will be.
Among allergen-specific biomarkers, peanut specific IgE levels
are useful for identification of patients at lowest risk of clinical
reactivity to peanut (levels ,0.35 kUa/L, absent or undetectable)
and for identification of those at highest risk for clinical reactivity
to peanut (levels $14 kUa/L (100% PPV, 95% C.V.). However,
they are less useful in the many peanut-sensitized patients who
have values in the range of 0.35–14 kUa/L [4,5]. Skin prick test
diameter can be useful in predicting the likelihood of clinical
reactivity to peanut, but as with peanut specific IgE levels, this
approach is greatly hampered by poor specificity and poor positive
predictive values in a substantial proportion of the population [7].
In addition, neither peanut SPT nor peanut specific IgE levels
reliably predict the severity of the clinical response. Peanut SPT
and specific IgE levels may remain positive years after clinical
tolerance towards peanut has been achieved [22].
One limitation in the study design used here is that DBPCFC
were not performed on the 200 subjects for ethical and practical
reasons. Peanut non-allergic subjects reported that they regularly
ate peanut. Diagnoses of peanut allergy were made by experienced
pediatric allergists based on recent convincing histories of peanut
induced anaphylaxis, peanut specific IgE, and peanut skin prick
test results. While some misclassification is possible, in our view,
the overlap in range of IL-10 values between the populations,
spanning almost three orders of magnitude, makes it extremely
unlikely that this parameter would serve as a useful diagnostic
marker of clinical tolerance with acceptable positive and negative
predictive values.
The primary focus in this study was testing the hypothesis that
globally enhanced plasma or serum IL-10 levels could provide a
sensitive and specific tool for determination of human clinical
tolerance to food antigens. For peanut allergy it did not. The
mechanisms that are responsible for ongoing clinical tolerance to
peanut in the 97–99% of the general population that is not
clinically allergic to peanut remain unclear. Thus, the broader
question of what combination of mechanisms is responsible for
establishing and maintaining oral tolerance to foods in most of the
human population remains controversial. Evidence suggests the
participation of multiple mechanisms, including elevated antigen-
specific (rather than global) IL-10, TGFb and/or IL-35 produc-
tion, antigen-driven CTLA4 expression, alterations in tryptophan
metabolism, anergy of food-specific T cells and activity of one or
more of the 15 regulatory T cell subsets putatively identified to
date [32,33].
In summary, we demonstrate that constitutive plasma IL-10
levels do not serve as a useful biomarker to discriminate clinical
tolerance to peanuts from peanut allergy in humans. Further
research is required to identify clinically useful markers by
distinguishing factors that differ quantitatively between those
who are peanut allergic and those who ingest peanut without
allergic reactions. With greater understanding of how tolerance is
achieved and maintained, identification of such biomarkers may
be possible.
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